Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...

Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

Although Libtayo faced QoQ revenue decline, which, besides slower-than-expected growth for Eylea HD, may have contributed to the stock's -10% penalty immediately post-Q3 earnings, Regeneron's ...

These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically ...

Regeneron collaborates with Truveta and leading ... Fianlimab (LAG3) for melanoma: Combining fianlimab and Libtayo, two potentially best-in-class checkpoint inhibitors, has the potential for ...